Further investigation into the downstream effects of ADAM10 upregulation in this context, including secretome analysis and examination of cell surface protein shedding, could provide insights into whether CD58 or other immune-related molecules are potential targets of ADAM10 in chemotherapy-treated ALL cells. Here, ADAM10 is linked to acute lymphoblastic leukemia.